Aligos Therapeutics entered into an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. for the development and commercialization of pevifoscorvir sodium, a first‑in‑class capsid assembly modulator, in Greater China. The agreement provides an upfront milestone payment of $25 million and allows Aligos to earn up to $420 million in additional clinical, regulatory and sales milestones, as well as tiered, high single‑digit royalties on net sales in the licensed territories.
The partnership leverages Amoytop’s established presence in the Greater China market, where more than 90 million people live with chronic hepatitis B. By granting Amoytop the rights to develop and commercialize pevifoscorvir sodium in Mainland China, Taiwan, Hong Kong and Macau, Aligos can accelerate the drug’s progress in a large patient population while retaining full development and commercialization rights in the United States, Europe, South Korea, Japan and all other markets.
The $25 million upfront payment extends Aligos’ cash runway into the fourth quarter of 2026, providing immediate liquidity for ongoing clinical development. The potential for up to $420 million in future milestones and royalties represents a significant upside, and the high single‑digit royalty structure aligns Aligos’ interests with Amoytop’s commercial performance in the region.
"We are pleased to build on our established relationship with Amoytop, a trusted partner through our preclinical antisense oligonucleotide (ASO) program, ALG‑170675, for chronic hepatitis B infection," said Lawrence Blatt, Ph.D., CEO of Aligos. "We believe pairing pevifoscorvir sodium with Pegbing—along with the ASCO collaboration—will enable differentiated combination regimens and more personalized treatment approaches for patients with chronic HBV infection across Greater China." Sun Li, Chairman and CEO of Amoytop, added, "Aligos is at the forefront of HBV innovation, and we are pleased to deepen our partnership with this outstanding team. We believe pevifoscorvir sodium has the potential to transform chronic HBV suppression, and we are proud to license this important program for Greater China."
The market reacted positively to the announcement, with analysts highlighting the immediate cash infusion and the strategic value of the partnership in accelerating the drug’s development and commercialization in a key market. The deal also positions Aligos to focus resources on pursuing similar strategies for pevifoscorvir sodium in other global markets, including the United States, Europe, Japan and South Korea.
Aligos’ pevifoscorvir sodium is currently in Phase 2 clinical trials (B‑SUPREME study). The second interim analysis is expected in the second half of 2026, with topline data slated for 2027. The drug received FDA Fast Track designation on April 14 2026, underscoring its potential to address unmet needs in chronic hepatitis B treatment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.